Hypercoagulabilty, venous thromboembolism, and death in patients with cancer

Summary

Venous thromboembolism (VTE) is a frequent complication of malignancy. The aim of this study was to investigate whether multi-state modelling may be a useful quantitative approach to dissect the complex epidemiological relationship between hypercoagulability, VTE, and death in cancer patients. We implemented a three-state/three-transition unidirectional illness-death model of cancer-associated VTE in data of 1,685 cancer patients included in a prospective cohort study, the Vienna Cancer and Thrombosis Study (CATS). During the two-year follow-up period, 145 (8.6%) patients developed VTE, 79 (54.5%) died after developing VTE, and 647 (38.4%) died without developing VTE, respectively. VTE events during follow-up were associated with a three-fold increase in the risk of death (Transition Hazard ratio (HR)=2.98, 95% confidence interval [CI]: 2.36-3.77, p< 0.001). This observation was independent of cancer stage. VTE events that occurred later during follow-up exerted a stronger impact on the risk of death than VTE events that occurred at earlier time points (HR for VTE occurrence one year after baseline vs at baseline=2.30, 95% CI: 1.28-4.15, p=0.005). Elevated baseline D-dimer levels emerged as a VTE-independent risk factor for mortality (HR=1.07, 95% CI: 1.05-1.08, p< 0.001), and also predicted mortality risk in patients who developed VTE. A higher Khorana Score predicted both the risk for VTE and death, but did not predict mortality after cancer-associated VTE. In conclusion, multi-state modeling represents a very potent approach to time-to-VTE cohort data in the cancer population, and should be used for both observational and interventional studies on cancer-associated VTE.

Keywords

Venous thrombosis - cancer - epidemiological studies

• References

• 1 Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013; 122: 2011-2018.
• 2 Carrier M, Cameron C, Delluc A. et al. Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis. Thromb Res 2014; 134: 1214-1219.
• 3 Khorana AA, Francis CW, Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 05: 632-634.
• 4 Agnelli G, George DJ, Kakkar AK. et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 601-609.
• 5 Campigotto F, Neuberg D, Zwicker JI. Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. J Thromb Haemost 2012; 10: 1449-1451.
• 6 Campigotto F, Neuberg D, Zwicker JI. Accounting for death as a competing risk in cancer-associated thrombosis studies. Thromb Res 2012; 129 (Suppl. 01) S85-87.
• 7 Ay C, Posch F, Kaider A. et al. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. J Thromb Haemost. 2014 Epub ahead of print.
• 8 Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 2389-2430.
• 9 Lotsch F, Konigsbrugge O, Posch F. et al. Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study. Thromb Res 2014; 134: 1008-1013.
• 10 Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381-387.
• 11 de Wreede LC, Fiocco M, Putter H. The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed 2010; 99: 261-274.
• 12 Ay C, Dunkler D, Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377-5382.
• 13 Ay C, Dunkler D, Pirker R. et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012; 97: 1158-1164.
• 14 Diao D, Wang Z, Cheng Y. et al. D-dimer: not just an indicator of venous thrombosis but a predictor of asymptomatic hematogenous metastasis in gastric cancer patients. PLoS One 2014; 09: e101125.
• 15 Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thromb Haemost 2012; 108: 1042-1048.
• 16 Carrier M DI. Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients (AVERT): 2014. Available at: http://www.clinicaltrials.gov
• 17 Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: The importance of multi-state models and competing risks analysis. Hepatology. 2014 Epub ahead of print.
• 18 Fiocco M, Putter H, van Houwelingen HC. Reduced-rank proportional hazards regression and simulation-based prediction for multi-state models. Stat Med 2008; 27: 4340-4358.